Souhaitez-vous accéder aux communiqués récents ?

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Phase 1b/2a study results published in Movement Disorders journalOral,...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Vitiligo Treatment...

Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Tenosynovitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical...

Evestia Clinical to merge with Atlantic Research Group

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's...

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. ...

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic...

Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. for an investigational PDE4 inhibitor